Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06650833 alone · 1 trial · 1 indication
Maximum observed concentration (Cmax) derived from plasma
Area under the plasma concentration-time profile derived from plasma from time 0 to time tau, the dosing interval (AUCtau), where tau=24 for QD dosing.
Maximum observed concentration (Cmax) derived from plasma
Area under the plasma concentration-time profile derived from plasma from time 0 to time tau, the dosing interval (AUCtau), where tau=24 for QD dosing.
| Arm | Type | Description |
|---|---|---|
| Single arm | EXPERIMENTAL | The study will have only one study group in a fixed-sequence type of design with two periods |
| Name | Type | Description |
|---|---|---|
| PF-06650833 alone | DRUG | In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone. |
| PF-06651600 alone | DRUG | In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone. |
| PF-06650833 together with PF-06651600 | DRUG | In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily. |
Inclusion Criteria: * Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD) * Male and female participants who are healthy as determined by medical evaluation including medical history, physical examination, including blood...
PF-06650833 is an investigational small molecule drug developed by Pfizer, Inc. It has been studied in a Phase 1 clinical trial involving healthy adult participants. The trial evaluated PF-06650833 in combination with another drug, PF-06651600, following multiple doses. PF-06650833 has not been approved by the FDA and remains in clinical development.
PF-06650833 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer sponsored the Phase 1 drug-drug interaction study of PF-06650833 conducted in the United States.
PF-06650833 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
PF-06650833 has been studied in one completed Phase 1 trial, NCT03827668, titled a drug-drug interaction study between PF-06650833 and PF-06651600 following multiple doses in healthy participants. The trial enrolled 15 healthy adult volunteers in the United States and was an uncontrolled study.
PF-06650833 is an investigational drug that has been studied in healthy adult volunteers in a Phase 1 drug-drug interaction trial. No approved therapeutic indication has been established for PF-06650833, and it remains in clinical development.